日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland

贝兰他单抗(Belantamab Mafodotin)单药治疗多次复发性多发性骨髓瘤:一项来自英国和爱尔兰共和国的回顾性研究

Watson, Edmund C R; Djebbari, Faouzi; Panitsas, Fotios; Vallance, Grant; Asher, Samir; Saeed, Malahat; Walker, Mairi; Powell, Matthew; Rampotas, Alexandros; Leary, Heather; Khera, Akhil; Atkinson, Angharad; Aung, Ni Ni; Brearton, Gillian; Froggatt, Joseph; Hassadi, Ezzat El; Gokkel, Ellen; Lawless, Sarah; Salhan, Beena; Shafeek, Salim; Lokare, Anand; Stirling, Carol; Oppermann, Udo; Soutar, Richard; Popat, Rakesh; Kyriakou, Charalampia; Ramasamy, Karthik

Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series

在既往接受过大量治疗的多发性骨髓瘤患者中,塞利尼索联合地塞米松(可联合或不联合硼替佐米)的治疗:病例系列研究

Aung, Nini; Bowers, Margaret; Brearton, Gillian; Charlton, Andrew; Craig, Joanne; Cullis, Jonathan; Dang, Ray; Donaldson, David; Drake, Mary; Hall, Rachel; Parkins, Elizabeth; Tighe, Jane; Bygrave, Ceri; Sheehy, Oonagh

Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome

对癌症患者在 COVID-19 感染前后血液学和生化指标的纵向分析揭示了与预后相关的特征。

Lee, R J; Wysocki, O; Bhogal, T; Shotton, R; Tivey, A; Angelakas, A; Aung, T; Banfill, K; Baxter, M; Boyce, H; Brearton, G; Copson, E; Dickens, E; Eastlake, L; Gomes, F; Hague, C; Harrison, M; Horsley, L; Huddar, P; Hudson, Z; Khan, S; Khan, U T; Maynard, A; McKenzie, H; Palmer, D; Robinson, T; Rowe, M; Thomas, A; Tweedy, J; Sheehan, R; Stockdale, A; Weaver, J; Williams, S; Wilson, C; Zhou, C; Dive, C; Cooksley, T; Palmieri, C; Freitas, A; Armstrong, A C

Erratum to 'Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome': [ESMO Open Volume 6, Issue 1, February 2021, 100005]

对“COVID-19 之前和期间癌症患者的血液学和生化参数的纵向特征分析揭示了与预后相关的特征”的勘误:[ESMO Open 第 6 卷,第 1 期,2021 年 2 月,100005]

Lee, R J; Wysocki, O; Bhogal, T; Shotton, R; Tivey, A; Angelakas, A; Aung, T; Banfill, K; Baxter, M; Boyce, H; Brearton, G; Copson, E; Dickens, E; Eastlake, L; Gomes, F; Hague, C; Harrison, M; Horsley, L; Huddar, P; Hudson, Z; Khan, S; Khan, U T; Maynard, A; McKenzie, H; Palmer, D; Robinson, T; Rowe, M; Thomas, A; Tweedy, J; Sheehan, R; Stockdale, A; Weaver, J; Williams, S; Wilson, C; Zhou, C; Dive, C; Cooksley, T; Palmieri, C; Freitas, A; Armstrong, A C

CD56 positive central nervous system plasmacytosis in a patient with refractory CD56 negative primary plasma cell leukaemia

CD56阳性中枢神经系统浆细胞增多症,发生于难治性CD56阴性原发性浆细胞白血病患者

Yong, Jun; Schofield, Jeremy; Lawton, David; Brearton, Gillian